Methods of treating nitric oxide and cytokine mediated disorders
DC CAFC
First Claim
1. A method of treating a nitric oxide or cytokine mediated disorder in a cell, comprising administering a biologically effective amount of at least one induction suppressor of an inducible nitric oxide synthase or a cytokine, wherein said induction suppressor is an inhibitor of mevalonate synthesis, an inhibitor of the farnesylation of Ras, an antioxidant, an enhancer of intracellular cAMP, an enhancer of protein kinase A (PKA), an inhibitor of NF-kβ
- activation, an inhibitor of Ras/Raf/MAP kinase pathway, an inhibitor of mevalonate pyrophosphate decarboxylase or an inhibitor of farnesyl pyrophosphate.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer'"'"'s and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP. Methods of treating a nitric oxide or cytokine mediated disorder in a cell comprising administering a biologically effective amount of at least one induction suppressor of an inducible nitric oxide synthase or a cytokine is also described.
112 Citations
50 Claims
-
1. A method of treating a nitric oxide or cytokine mediated disorder in a cell, comprising administering a biologically effective amount of at least one induction suppressor of an inducible nitric oxide synthase or a cytokine, wherein said induction suppressor is an inhibitor of mevalonate synthesis, an inhibitor of the farnesylation of Ras, an antioxidant, an enhancer of intracellular cAMP, an enhancer of protein kinase A (PKA), an inhibitor of NF-kβ
- activation, an inhibitor of Ras/Raf/MAP kinase pathway, an inhibitor of mevalonate pyrophosphate decarboxylase or an inhibitor of farnesyl pyrophosphate.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)
-
47. A method of treating a nitric oxide mediated disorder in a cell, comprising administering a biologically effective amount of at least one induction suppressor of an inducible nitric oxide synthase, wherein said induction suppressor is an inhibitor of mevalonate synthesis, an inhibitor of the farnesylation of Ras, an antioxidant, an enhancer of intracellular cAMP, an enhancer of protein kinase A (PKA), an inhibitor of NF-kβ
- activation, an inhibitor of Ras/Raf/MAP kinase pathway, an inhibitor of mevalonate pyrophosphate decarboxylase or an inhibitor of farnesyl pyrophosphate.
- View Dependent Claims (48)
-
49. A method of treating a cytokine mediated disorder in a cell, comprising administering a biologically effective amount of at least one induction suppressor of a cytokine, wherein said induction suppressor is an inhibitor of mevalonate synthesis, an inhibitor of the farnesylation of Ras, an antioxidant, an enhancer of intracellular cAMP, an enhancer of protein kinase A (PKA), an inhibitor of NF-kβ
- activation, an inhibitor of Ras/Raf/MAP kinase pathway, an inhibitor of mevalonate pyrophosphate decarboxylase or an inhibitor of farnesyl pyrophosphate.
- View Dependent Claims (50)
Specification
-
- Resources
-
Current AssigneeMUSC Foundation For Research Development (State of South Carolina)
-
Original AssigneeMedical University of South Carolina (State of South Carolina), MUSC Foundation For Research Development (State of South Carolina)
-
InventorsSingh, Inderjit
-
Primary Examiner(s)GITOMER, RALPH J
-
Application NumberUS09/579,791Time in Patent Office978 DaysField of Search435/4, 435/26, 514/440, 514/562, 514/563, 514/564US Class Current435/4CPC Class CodesA61K 31/00 Medicinal preparations cont...A61K 31/137 Arylalkylamines, e.g. amphe...A61K 31/145 having sulfur, e.g. thiuram...A61K 31/175 having the group , >N—C(O)...A61K 31/192 having aromatic groups, e.g...A61K 31/198 Alpha-amino acids, e.g. ala...A61K 31/20 having a carboxyl group bou...A61K 31/275 Nitriles; IsonitrilesA61K 31/343 condensed with a carbocycli...A61K 31/35 having six-membered rings w...A61K 31/352 condensed with carbocyclic ...A61K 31/366 having six-membered rings, ...A61K 31/40 having five-membered rings ...A61K 31/4015 having oxo groups directly ...A61K 31/4196 1,2,4-TriazolesA61K 31/472 Non-condensed isoquinolines...A61K 31/522 having oxo groups directly ...A61K 31/661 Phosphorus acids or esters ...A61K 31/7056 containing five-membered ri...A61K 31/7076 containing purines, e.g. ad...View All
